Helliwell PS, Deodhar A, Gottlieb AB, et al. - Researchers conducted this Phase 2 trial to evaluate the performance of psoriatic arthritis (PsA) composite indices and assessed the effect of guselkumab, a human monoclonal antibody with high-affinity for the p19-subunit of interleukin-23, on achieving low disease activity or remission. Active PsA patients (≥ 3 tender and ≥ 3 swollen joints, C-reactive protein ≥ 0.3 mg/dL, ≥ 3% body-surface-area psoriasis involvement) were randomized 2:1 to subcutaneous guselkumab 100 mg (N = 100) or placebo (N = 49) at Week 0, Week 4 and q8w through Week 44. According to findings, guselkumab showed effectiveness in achieving low disease activity/remission based on all evaluated composite indices of PsA. The use of composite index in PsA and clinic trials requires careful consideration in order to optimize feasibility and efficiency of instruments. In patients achieving DAPSA low disease activity vs other indices, residual skin disease and enthesitis were marginally more prominent.